GlobeNewswire

Cornell receives $35M to support cassava development for smallholder farmers in sub-Saharan Africa

Dela

Ithaca, New York, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Cassava is vital to the food security of millions of Africans who eat some form of the root crop daily. Although cassava breeders are making progress, they still face significant challenges in developing disease-resistant varieties that also increase overall yield and respond to the needs of smallholder farmers and processors. Cornell University will expand international efforts to deliver improved varieties of cassava to smallholder farmers in sub-Saharan Africa with $35 million in new funding from the Bill & Melinda Gates Foundation and UK aid from the United Kingdom.

"This grant funds a second five-year phase that will allow us to build on previous work and focus on getting improved varieties into farmers' fields," said Ronnie Coffman, international plant breeder and director of Cornell's International Programs in the College of Agriculture and Life Sciences, who leads the project. 

During Phase 1 of the Next Generation Cassava Breeding project - also funded by the Gates Foundation and UK aid from 2012 to 2017 - researchers shortened the breeding cycle for new cassava varieties by improving flowering and using genomic selection. Through analyzing plant genotypes and identifying cassava lines with desirable traits, such as resistance to cassava brown streak disease or high dry matter content, breeders also improved their ability to make selections based on genetics and probability without having to wait for seedlings to reach adulthood. These methods save breeding time for a crop where flowering and sexual propagation are issues.

Another goal of Phase 1 was to make cassava genomic information publicly accessible on an open database. Cassava researchers all over the world are now comparing results and improving breeding programs without duplicating efforts by using Cassavabase. To reduce cost per progeny and improve the quality of data uploaded to Cassavabase in Phase 2, NextGen researchers will use additional methods of whole genome sequencing. 

"Our focus for the next five years will be to translate this research into breeding practices to increase impact," said Chiedozie Egesi, NextGen project director and adjunct professor of plant breeding and genetics at Cornell, who is based at the International Institute of Tropical Agriculture (IITA) in Nigeria. "A key goal in Phase 2 will be to identify traits preferred by farmers and end-users and incorporate them into new cassava lines to ensure that varieties are responsive to people's needs."

Egesi said, "We believe we will accelerate genetic gain as well as adopted genetic gain, increase the yields and resilience of cassava production by smallholder farmers, and move African cassava breeding toward greater capacity."

"Among the 30 new clones developed at IITA using our methods, 10 had higher dry matter yield than any clone currently available for smallholder farmers in Nigeria," said Jean-Luc Jannink, a research plant geneticist with the United States Department of Agriculture, Agricultural Research Service  (USDA-ARS) and Cornell adjunct associate professor in the Department of Plant Breeding and Genetics at Cornell. "Dry matter yield is a close proxy to food yield. Conservatively, we believe that we will increase the rate of genetic gain in cassava by 30 to 50 percent." 

Said Peter Kulakow, IITA cassava breeder and geneticist: "Genetic gain is a measure of the improvement of plant performance between generations and a goal of most modern breeding programs. Swifter improvements mean more new varieties can be tested and released." 

At the sixth annual Next Gen Cassava meeting, Feb. 19-24 in Dar es Salaam, Tanzania, teams of NextGen breeders, geneticists, data analysts, computer programmers, food technologists, social scientists and crop protectionists will be focusing on goals for Phase 2 and discussing how to better coordinate and leverage the exchange of germplasm and genotypic and phenotypic data from each other.

Developing capacity for sustainable breeding programs

Compared with other major staples like maize, rice and wheat, cassava has undergone few advances in productivity and yield over the last 50 years, making it an ideal candidate for breeding improvement. Because cassava is clonally propagated and has a low multiplication rate, it can take almost six to eight years before a new cassava variety makes it from breeders' nurseries through field trials to farmers' fields. Most breeding efforts focus on product development  - goals set by scientists and researchers without accounting for the preferences of farmers. In practice, this can result in poor adoption of new varieties and unrealized potential. 

"Breeders must be able to more quickly develop cassava varieties that resist diseases, are climate resilient and meet the needs of end-users and consumers," said Egesi.

Strengthening the capacity of national breeding programs will be critical in achieving self-sustaining breeding systems in sub-Saharan Africa. Over the next five years, NextGen researchers will continue to train the next generation of sub-Sahara African cassava breeders in modern plant breeding techniques like genomic selection and improved breeding methods.

International and regional partnerships are another important element of sustainability. NextGen researchers are reaching out to their counterparts in Ghana, Rwanda, Mozambique, Sierra Leone and the Democratic Republic of Congo to create a broader network of researchers who can work together to improve livelihoods and food security.

In Africa, NextGen collaborators include the International Institute of Tropical Agriculture, the National Root Crops Research Institute and West Africa Centre for Crop Improvement in Nigeria; the National Crops Resources Research Institute and Makerere University in Uganda; and the Tanzania Agricultural Research Institute in Tanzania. In South America, collaborators include Embrapa in Brazil and the International Center for Tropical Agriculture in Colombia. In the US, collaborators are Cornell University (who leads the project), the Boyce Thompson Institute at Cornell, the University of Hawaii, and the USDA-ARS in Ithaca.

For more information see www.nextgencassava.org   

 

 

# # #

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d1896398-975a-4943-85b0-4f4b165f5678

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4e3e5f6e-d4b9-45d1-b74d-8248eb7bb1ba

Linda McCandless
Cornell University 
6072275920
llm3@cornell.edu



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cornell University via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum